Harrow Announces Availability of VEVYE® (Cyclosporine Ophthalmic Solution) 0.1%, the First and Only Cyclosporine-Based Product Indicated for Treating Both Signs and Symptoms of Dry Eye Dis...
Harrow, Inc. (HROW)
Last harrow, inc. earnings: 11/13 04:21 pm
Check Earnings Report
Company Research
Source: Business Wire
VEVYE® Offers Rapid Onset with Clinically and Statistically Meaningful ImprovementBeginning as Early as 15 Days1 with Sustained Improvement over 56 Weeks2VEVYE® Patients to Have Access to a 100% Money-Back Guarantee Program3 NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that VEVYE® (cyclosporine ophthalmic solution) 0.1%, a patented, non-preserved, twice-daily (BID) dosed prescription drug based on a “water-free” semifluorinated alkane eyedrop technology, is now available in the U.S. – and includes a 100% Money-Back Guarantee program. VEVYE, uniquely dispensed in a 10 microliter drop, is the first and only cyclosporine-based product indicated for treating both the signs and symptoms of dry eye disease (DED).In commenting on the announcement, Mark L. Baum, Chairman and Chief Executive Officer of Harrow, said, “We are thrilled to announce the availability of VEVYE for our customers and their patients. VEVYE is
Show less
Read more
Impact Snapshot
Event Time:
HROW
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HROW alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HROW alerts
High impacting Harrow, Inc. news events
Weekly update
A roundup of the hottest topics
HROW
News
- Harrow Will Release First Quarter 2024 Financial Results After Market Close on May 13, 2024Business Wire
- Harrow Health, Inc. (NASDAQ: HROW) is now covered by analysts at Craig Hallum. They set a "buy" rating and a $24.00 price target on the stock.MarketBeat
- Melt Pharmaceuticals Closes $24 Million Series B Preferred Stock FinancingBusiness Wire
- Harrow Health, Inc. (NASDAQ: HROW) had its price target lowered by analysts at B. Riley from $30.00 to $26.00. They now have a "buy" rating on the stock.MarketBeat
- Harrow Health, Inc. (NASDAQ:HROW) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
HROW
Earnings
- 11/13/23 - Miss
HROW
Sec Filings
- 4/26/24 - Form DEFA14A
- 4/26/24 - Form DEF
- 4/25/24 - Form 4
- HROW's page on the SEC website